Cargando…

Vaccination against GIP for the Treatment of Obesity

BACKGROUND: According to the WHO, more than 1 billion people worldwide are overweight and at risk of developing chronic illnesses, including cardiovascular disease, type 2 diabetes, hypertension and stroke. Current therapies show limited efficacy and are often associated with unpleasant side-effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fulurija, Alma, Lutz, Thomas A., Sladko, Katja, Osto, Melania, Wielinga, Peter Y., Bachmann, Martin F., Saudan, Philippe
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2525840/ https://www.ncbi.nlm.nih.gov/pubmed/18779862 http://dx.doi.org/10.1371/journal.pone.0003163

Ejemplares similares

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
por: Fukuda, Makoto
Publicado: (2021)

Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes
por: Spohn, Gunther, et al.
Publicado: (2014)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022)

Absence of GIP secretion alleviates age-related obesity and insulin resistance
por: Kanemaru, Yoshinori, et al.
Publicado: (2020)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011)

Correlates of immunity to Group A Streptococcus: a pathway to vaccine development
por: Frost, Hannah, et al.
Publicado: (2023)

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Bacterially Produced Recombinant Influenza Vaccines Based on Virus-Like Particles
por: Jegerlehner, Andrea, et al.
Publicado: (2013)

Marked Cortisol Production by Intracrine ACTH in GIP-Treated Cultured Adrenal Cells in Which the GIP Receptor Was Exogenously Introduced
por: Fujii, Hiroko, et al.
Publicado: (2014)

GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
por: Kim, Su-Jin, et al.
Publicado: (2012)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017)

Dysglycemia Shapes Visceral Adipose Tissue’s Response to GIP, GLP-1 and Glucagon in Individuals with Obesity
por: Morais, Tiago, et al.
Publicado: (2023)

Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women
por: Garg, Gaurav, et al.
Publicado: (2015)

Pleiotropic Effects of GIP on Islet Function Involve Osteopontin
por: Lyssenko, Valeriya, et al.
Publicado: (2011)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice
por: Hasib, Annie, et al.
Publicado: (2016)

Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis
por: Góralska, Joanna, et al.
Publicado: (2020)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
por: Knerr, Patrick J., et al.
Publicado: (2022)

Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor
por: Könitzer, Jennifer D., et al.
Publicado: (2017)

GIP/MZT1 proteins orchestrate nuclear shaping
por: Batzenschlager, Morgane, et al.
Publicado: (2014)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

The effect of gastrointestinal pathogen panel (GIP) on antibiotic management
por: Saling, Christopher F., et al.
Publicado: (2021)

Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance
por: Ahlqvist, Emma, et al.
Publicado: (2013)

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
por: Lindquist, Peter, et al.
Publicado: (2022)

Gastric Inhibitory Polypeptide (GIP) Is Selectively Decreased in the Roux-Limb of Dietary Obese Mice after RYGB Surgery
por: Zhou, Jiaqiang, et al.
Publicado: (2015)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Physiological roles of the GIP receptor in murine brown adipose tissue
por: Beaudry, Jacqueline L., et al.
Publicado: (2019)

721. Effect of Gastrointestinal Pathogen Panel (GIP) in Antibiotic Management
por: Saling, Christopher F, et al.
Publicado: (2020)

GIP receptor agonism blocks chemotherapy-induced nausea and vomiting
por: Borner, Tito, et al.
Publicado: (2023)

Versatile Virus-Like Particle Carrier for Epitope Based Vaccines
por: Tissot, Alain C., et al.
Publicado: (2010)

Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines
por: Gomes, Ariane C., et al.
Publicado: (2017)

Enhanced agonist residence time, internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor desensitization and long‐term impairment of the GIP system
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2019)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

GIP Contributions to the Regulation of Centromere at the Interface Between the Nuclear Envelope and the Nucleoplasm
por: Chabouté, Marie-Edith, et al.
Publicado: (2016)

GIP-induced vasodilation in human adipose tissue involves capillary recruitment
por: Asmar, Meena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hq82bsvkm195tth2io832fpaut